SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Clara Barton

PatientClara Barton
Date of birth1973-12-25
IdentifiersMRN HR-NI024-SYN; SSN (made up) 000-24-3357
Document date2026-02-03
AuthorEleanor Whitcombe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week sertraline tolerability and safety check; psychiatry consultation today. [S]

History of Present Illness

Ms. Barton returns two weeks after starting sertraline 50 mg each morning for a recurrent depressive episode. She took the two weeks of medical leave and has not been to the office, though she admits to answering some messages from home. She had mild nausea and loose stools in the first week, which have settled; she has had no headache, restlessness, agitation, or bleeding. She has missed no doses. She still wakes at 3 or 4 in the morning but now sleeps four to five hours. Her energy and interest are still low, though she walked with a friend twice this week. She has had no suicidal thoughts since the first visit and keeps her safety plan in her bag. Her first cognitive behavioral therapy session is booked for this week. She saw Dr. Mendes of psychiatry this morning. [S]

ElementDetail
Medication toleranceMild nausea and loose stools in week one, now settled; no agitation or restlessness
AdherenceNo missed doses
SleepFour to five hours, with early waking
WorkOn two weeks of medical leave; answering some messages from home
SafetyNo suicidal thoughts since intake; safety plan carried
PHQ-916, down from 18

Review of Systems

SystemResultFinding
GastrointestinalNegativeEarly nausea and loose stools resolved; no bleeding
NeurologicalNegativeNo headache, tremor, or restlessness
ConstitutionalPositiveFatigue persists; appetite slightly better
PsychiatricPositiveLow mood and interest, early waking; no suicidal thoughts, elevated mood, or racing thoughts

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Sertraline 50 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morningOral route2026-01-20 to 2026-03-03completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-02-03Body height152cmS
2026-02-03Body weight49.6kgS
2026-02-03Body mass index (BMI) [Ratio]21.5kg/m2S
2026-02-03Systolic blood pressure116mm[Hg]S
2026-02-03Diastolic blood pressure72mm[Hg]S
2026-02-03Heart rate78/minS
2026-02-03Respiratory rate14/minS
2026-02-03Body temperature36.5CelS
2026-02-03Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-02-03Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]16{score}S

Physical Exam

Vital signs recorded on 2026-02-03; see the Vital Signs section. [S]

SystemFinding
GeneralSmall, neatly dressed, tired
Mental statusAlert and cooperative; speech soft and slow; mood "a little less heavy"; affect constricted; thought process linear; no suicidal ideation; no psychotic features; insight and judgment good
NeurologicalNo tremor

Problems

ProblemClinical statusVerificationCodeProvenance
Major depressive disorder, recurrent, moderate (moderately severe symptoms at intake), after a prolonged humanitarian deployment; synthetic modern diagnosis linked to her documented periods of depression and nervous prostrationactiveconfirmed F33.1S — Synthetic modern diagnosis. Her periods of depression and nervous prostration are documented in her own words (D); calling them major depression is a retrospective interpretation (R), and no diagnosis was made in her lifetime.
Occupational burnout after eighteen months leading field medical relief in a war zoneactiveconfirmed Z73.0S — Synthetic contributing factor echoing her documented exhaustion after wartime relief work; burnout is an occupational phenomenon, not a mental disorder.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPHQ-9Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuationCompleted today16, down from 18 at intake (11 percent)
Medication safetySSRI tolerability check two weeks after starting2 weeks after starting and after each dose changeCompleted todayEarly nausea and loose stools settled; no activation, agitation, or bleeding
SurveySuicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9)Every visit during active treatmentCompleted todayNo suicidal thoughts, intent, plan, or behavior since intake; PHQ-9 item 9 scored 0. Protective factors unchanged. Safety plan reviewed: she carries her copy and has 988 and the clinic number saved
Medication safetyAdherence and adverse-effect reviewEvery visit during active treatmentCompleted todayNo missed doses; no headache, tremor, sexual side effects, or bleeding
SurveyBipolar screen at the initial workupOnce, at the initial depression workupCompleted todayPsychiatric interview today found no past manic or hypomanic episode; no Mood Disorder Questionnaire score is recorded
ReferralPsychiatry consultationFor recurrent or complex episodesCompleted todaySeen today; diagnosis confirmed; combination treatment and titration plan agreed
Self-managementPsychotherapy, sleep, activity, and social contactEvery visit during active treatmentCompleted todayCBT starts this week; two walks with a friend; sleep four to five hours
LaboratoryLithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS)Only on those drugsNot indicatedTreated with an SSRI only

Goal progress:

Guideline basis: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Depression review in four weeks, six weeks after starting sertraline. Next scheduled visit 2026-03-03: six-week depression treatment review. [S]